Clinical Trial Update: A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough [Phase 2]

View source ↗

Summary

Phase 2 dose-escalation study of BLU-5937 in chronic refractory cough was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• BLU-5937 (BLU-5937)

Snippet

Sponsor: Bellus Health Inc. - a GSK company | Conditions: Chronic Refractory Cough | Phase 2 | Status: TERMINATED | Results posted: 2021-08-03